nach oben

Current Oncology Reports

Erschienen in:

01.02.2019 | Leukemia (A Aguayo, Section Editor)

New Treatment Options for Acute Myeloid Leukemia in 2019

verfasst von: Marco Cerrano, Raphael Itzykson

Erschienen in: Current Oncology Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The extensive genomic characterization of acute myeloid leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We review relevant data that have led to recent approval of new targeted therapies in AML and discuss the most promising drugs currently in development in this disease.

Recent Findings

New formulations of cytotoxic agents, namely CPX-351 and gemtuzumab ozogamicin, improve the outcome of defined subgroup of patients. Midostaurin added to intensive chemotherapy is approved in FLT3-mutated AML. More selective FLT3 inhibitors and the IDH inhibitors enasidenib and ivosidenib have shown significant single agent activity in the relapsed setting, and preliminary results of combination strategies are encouraging. The addition of the BCL2 inhibitor venetoclax appears to markedly improve the results of hypomethylating agents.

Summary

The therapeutic armamentarium of AML now includes novel cytotoxic drugs, drugs targeting recurrent oncogenes, or functional vulnerabilities of leukemic cells. Further work is required to optimize their integration to the current framework of AML management, including allogeneic stem cell transplantation.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. https://doi.org/10.1182/blood-2016-03-643544.CrossRefPubMed

Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74. https://doi.org/10.1056/NEJMoa1301689.CrossRef

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21. https://doi.org/10.1056/NEJMoa1516192.CrossRefPubMedPubMedCentral

Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35:934–46. https://doi.org/10.1200/JCO.2016.71.2208.CrossRefPubMed

Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593–606. https://doi.org/10.1016/S0140-6736(18)31041-9.CrossRefPubMed

Michaelis LC, Klepin HD, Walter RB. Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. Expert Opin Pharmacother. 2018;19:865–82. https://doi.org/10.1080/14656566.2018.1465562.CrossRefPubMed

Dombret H, Itzykson R. How and when to decide between epigenetic therapy and chemotherapy in patients with AML. Hematology Am Soc Hematol Educ Program. 2017;2017:45–53.PubMedPubMedCentral

Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53–61. https://doi.org/10.1182/blood-2015-08-604520.CrossRefPubMedPubMedCentral

Crisà E, Cerrano M, Gatti T, Giai V, Aguzzi C, Boccadoro M, et al. The combination of fludarabine + citarabine + idarubicin (FLAI), followed by post-remission maintenance, is a safe and effective treatment for elderly patients with AML or high risk MDS. Ann Hematol Oncol. 2015;2(8):1056.

10.

Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J Clin Oncol. 2013;31:3360–8. https://doi.org/10.1200/JCO.2012.47.4874.CrossRefPubMed

11.

Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441–8. https://doi.org/10.1200/JCO.2011.37.1286.CrossRefPubMed

12.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival M-EM, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 2018;32:2352–62. https://doi.org/10.1038/s41375-018-0135-8.CrossRefPubMedPubMedCentral

13.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. https://doi.org/10.1182/blood-2016-08-733196.CrossRefPubMedPubMedCentral

14.

Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122:1384–94. https://doi.org/10.1182/blood-2013-04-496596.CrossRefPubMed

15.

Foran JM, Sun Z, Claxton DF, Lazarus HM, Thomas ML, Melnick A, et al. North American Leukemia, Intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN Cancer Research Group (E2906). ASH Meeting Abstracts 2015;126:217–217.

16.

Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, et al. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia. 2017;31:310–7. https://doi.org/10.1038/leu.2016.225.CrossRefPubMed

17.

Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, et al. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 2017;129:1636–45. https://doi.org/10.1182/blood-2016-10-740613.CrossRefPubMed

18.

Burnett AK, Hills RK, Nielsen OJ, Freeman S, Ali A, Cahalin P, et al. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 trial. Leukemia. 2018;32:2693–714. https://doi.org/10.1038/s41375-018-0148-3.CrossRefPubMedPubMedCentral

19.

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, et al. Randomized phase II study of clofarabine-based consolidation for younger adults with acute myeloid leukemia in first remission. J Clin Oncol. 2017;35:1223–30. https://doi.org/10.1200/JCO.2016.70.4551.CrossRefPubMed

20.

Chen EC, Fathi AT, Brunner AM. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Onco Targets Ther. 2018;11:3425–34. https://doi.org/10.2147/OTT.S141212.CrossRefPubMedPubMedCentral

21.

• Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36:2684–92. https://doi.org/10.1200/JCO.2017.77.6112. This phase III trial showed the superiority of CPX-351 compared to 7+3 chemotherapy in elderly fit patients with secondary, therapy-related or de novo AML with myelodysplastic syndrome-related abnormalities. CrossRefPubMedPubMedCentral

22.

Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854–60. https://doi.org/10.1182/blood-2013-01-466706.CrossRefPubMedPubMedCentral

23.

Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31:1855–68. https://doi.org/10.1038/leu.2017.187.CrossRefPubMed

24.

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34:972–9. https://doi.org/10.1200/JCO.2015.64.0060.CrossRefPubMed

25.

Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie J-N, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508–16. https://doi.org/10.1016/S0140-6736(12)60485-1.CrossRefPubMed

26.

Burnett A, Cavenagh J, Russell N, Hills R, Kell J, Jones G, et al. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica. 2016;101:724–31. https://doi.org/10.3324/haematol.2016.141937.CrossRefPubMedPubMedCentral

27.

Taksin A-L, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21:66–71. https://doi.org/10.1038/sj.leu.2404434.CrossRefPubMed

28.

• Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial. Haematologica. 2018. https://doi.org/10.3324/haematol.2018.188888. This is an independent review of the ALFA-0701 trial which confirmed the event-free survival advantage of addition of fractionated gemtuzumab ozogamicin to intensive chemotherapy.

29.

Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986–96. https://doi.org/10.1016/S1470-2045(14)70281-5.CrossRefPubMedPubMedCentral

30.

Sedov V, Stuart RK. Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. Ther Adv Hematol. 2017;8:185–95. https://doi.org/10.1177/2040620717703012.CrossRefPubMedPubMedCentral

31.

Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, et al. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017;102:1709–17. https://doi.org/10.3324/haematol.2017.168732.CrossRefPubMedPubMedCentral

32.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16:1025–36. https://doi.org/10.1016/S1470-2045(15)00201-6.CrossRefPubMedPubMedCentral

33.

Assi R, Ravandi F. FLT3 inhibitors in acute myeloid leukemia: choosing the best when the optimal does not exist. Am J Hematol. 2018;93:553–63. https://doi.org/10.1002/ajh.25027.CrossRefPubMed

34.

Pratz KW, Levis M. How I treat FLT3-mutated AML. Blood. 2017;129:565–71. https://doi.org/10.1182/blood-2016-09-693648.CrossRefPubMedPubMedCentral

35.

• Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377:454–64. https://doi.org/10.1056/NEJMoa1614359. The RATIFY trial showed that the addition of midostaurin to intensive chemotherapy significantly prolongs overall survival in FLT3 -mutated AML. CrossRefPubMedPubMedCentral

36.

Larson RA, Mandrekar SJ, Sanford BL, Laumann K, Geyer SM, Bloomfield CD, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. ASH Meeting Abstract 2017;130:145–145.

37.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691–9. https://doi.org/10.1016/S1470-2045(15)00362-9.CrossRefPubMed

38.

Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121:4655–62. https://doi.org/10.1182/blood-2013-01-480228.CrossRefPubMedPubMedCentral

39.

Rautenberg C, Nachtkamp K, Dienst A, Schmidt PV, Heyn C, Kondakci M, et al. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. Eur J Haematol. 2017;98:348–54. https://doi.org/10.1111/ejh.12832.CrossRefPubMed

40.

Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3 -ITD mutated acute myeloid leukemia. Am J Hematol. 2018;93:1136–41. https://doi.org/10.1002/ajh.25198.CrossRefPubMed

41.

Chen Y-B, Li S, Lane AA, Connolly C, Del Rio C, Valles B, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20:2042–8. https://doi.org/10.1016/j.bbmt.2014.09.007.CrossRefPubMedPubMedCentral

42.

Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3 -ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175:496–504. https://doi.org/10.1111/bjh.14260.CrossRefPubMedPubMedCentral

43.

Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia: sorafenib after HSCT for FLT3-mutated AML. Cancer. 2017;123:2867–74. https://doi.org/10.1002/cncr.30680.CrossRefPubMed

44.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19:889–903. https://doi.org/10.1016/S1470-2045(18)30240-7.CrossRefPubMedPubMedCentral

45.

Cortes J, Khaled S, Martinelli G, Perl AE, Ganguly S, et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication–mutated (mut) relapsed/refractory AML in the phase 3, randomized, controlled quantum-R trial. EHA Meeting Abstracts 2018, 218882 https://learningcenter.ehaweb.org/eha/2018/stockholm/218882/jorge.cortes.quizartinib.significantly.prolongs.overall.survival.in.patients.html.

46.

Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, et al. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017;130:48–58. https://doi.org/10.1182/blood-2016-04-711820.CrossRefPubMedPubMedCentral

47.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18:1061–75. https://doi.org/10.1016/S1470-2045(17)30416-3.CrossRefPubMedPubMedCentral

48.

Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Iida H, Morita S, et al. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: an open-label phase 1 study. Cancer Sci. 2018;109:3235–44. https://doi.org/10.1111/cas.13749.CrossRefPubMedPubMedCentral

49.

Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, et al. A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018;2:825–31. https://doi.org/10.1182/bloodadvances.2018015925.CrossRefPubMedPubMedCentral

50.

Cortes JE, Kantarjian HM, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Daver NG, Pemmaraju N, Jabbour E, Estrov Z, Ramachandran A, Paradela J, Pond B, Ravandi F, Vusirikala M, Patel PA, Levis MJ, Perl AE, Andreeff M, Collins R Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. ASCO Meeting Abstracts 2016;34:7008–7008. https://doi.org/10.1200/JCO.2016.34.15_suppl.7008.

51.

Nassereddine S, Lap CJ, Haroun F, Tabbara I. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Ann Hematol. 2017;96:1983–91. https://doi.org/10.1007/s00277-017-3161-0.CrossRefPubMed

52.

• Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–31. https://doi.org/10.1182/blood-2017-04-779405. This large phase I/II trial evaluated enasidenib in IDH2-mutated relapsed/refractory AML, showing an overall response rate of 40%, and a prolonged duration of response in patients achieving complete remission. CrossRefPubMedPubMedCentral

53.

Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130:732–41. https://doi.org/10.1182/blood-2017-04-779447.CrossRefPubMedPubMedCentral

54.

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018;559:125–9. https://doi.org/10.1038/s41586-018-0251-7.CrossRefPubMedPubMedCentral

55.

Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018;24:1167–77. https://doi.org/10.1038/s41591-018-0115-6.CrossRefPubMedPubMedCentral

56.

• DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386–98. https://doi.org/10.1056/NEJMoa1716984. Ivosidenib efficacy was demonstrated in this large phase I dose escalation and dose-expansion study including IDH1 -mutated relapsed/refractory AML patients. CrossRefPubMed

57.

DiNardo CD, Stein AS, Stein EM, Fathi AT, Schuh AC, Montesinos Fernández P, et al. Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). ASCO Meeting Abstracts 2018;36:7042–7042. https://doi.org/10.1200/JCO.2018.36.15_suppl.7042.

58.

Bykov VJN, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol. 2016;6:21. https://doi.org/10.3389/fonc.2016.00021.CrossRefPubMedPubMedCentral

59.

Sallman D, Dezern A, Sweet K, Steensma D, Cluzeau T, Sekeres M, et al. Phase 1b/2 combination study of APR-246 and azacitidine (aza) in patients with tp53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). EHA Meeting Abstracts 2018, 214477 https://learningcenter.ehaweb.org/eha/2018/stockholm/214477/david.sallman.phase.1b.2.combination.study.of.apr246.and.azacitidine.28aza29.in.html?f=media=1

60.

Cortes JE, Heidel FH, Heuser M, Fiedler W, Smith BD, Robak T, et al. A phase 2 randomized study of low dose Ara-C with or without Glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. ASH Meeting Abstracts 2016;128:99–99.

61.

Martinelli G, Pappayannidis C, Yee K, Vey N, Drummond M, Kelly K, et al. Phase 1b results of idasanutlin + cytarabine (ara-c) in acute myeloid leukemia (AML) patients (pts). EHA Meeting Abstracts 2018, 135260 https://learningcenter.ehaweb.org/eha/2018/stockholm/214477/david.sallman.phase.1b.2.combination.study.of.apr246.and.azacitidine.28aza29.in.html?f=media=1

62.

DeAngelo DJ, Jonas BA, Liesveld J, O’Dwyer M, Bixby D, Advani AS, et al. GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML. ASCO Meeting Abstracts 2017;35: 2520–2520. https://doi.org/10.1200/JCO.2017.35.15_suppl.2520.

63.

Bhatnagar B, Walker AR, Mims AS, Vasu S, Klisovic RB, Behbehani G, Blachly JS, Larkin KTM, Long M, Zhao Q, Ranganathan P, Byrd JC, Blum WG, Garzon R Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia. ASCO Meeting Abstracts. 2018;36: 7048–7048. https://doi.org/10.1200/JCO.2018.36.15_suppl.7048.

64.

Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, et al. Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. Blood Adv. 2018;2:381–9. https://doi.org/10.1182/bloodadvances.2017013391.CrossRefPubMedPubMedCentral

65.

Fröhling S, Agrawal M, Jahn N, Fransecky LR, Baldus CD, Wäsch R, et al. CDK4/6 inhibitor palbociclib for treatment of KMT2A-rearranged acute myeloid leukemia: interim analysis of the AMLSG 23-14 trial. ASH Meeting Abstracts. 2016;128:1608–1608.

66.

Walker AR, Bhatnagar B, Marcondes AMQ, DiPaolo J, Vasu S, Mims AS, et al. Interim results of a phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with chemotherapy in patients with acute myeloid leukemia. ASH Meeting Abstracts. 2016;128:2831–2831.

67.

Byrne M, Donnellan W, Patel MR, Zeidan AM, Cherry M, Baer MR, et al. Preliminary results from an ongoing phase 1/2 study of INCB053914, a pan-proviral integration sites for moloney virus (PIM) kinase inhibitor, in patients with advanced hematologic malignancies. ASH Meeting Abstracts. 2017;130:2585–2585.

68.

Garcia-Manero G, Yang H, Fang Z, Kantarjian HM, DiNardo CD, Jabbour EJ, et al. Phase 1 results of FF-10501-01, a novel inosine 5’-monophosphate dehydrogenase inhibitor, in advanced acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), including hypomethylating agent (HMA) failures. ASH Meeting Abstracts. 2016;128:1640–1640.

69.

Letai A. Functional precision cancer medicine—moving beyond pure genomics. Nat Med. 2017;23:1028–35. https://doi.org/10.1038/nm.4389.CrossRefPubMed

70.

Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018;132:1007–12. https://doi.org/10.1182/blood-2018-03-828269.CrossRefPubMedPubMedCentral

71.

Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106–17. https://doi.org/10.1158/2159-8290.CD-16-0313.CrossRefPubMedPubMedCentral

72.

Wei A, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL, et al. Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes. Blood. 2017;130:890.CrossRef

73.

DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216–28. https://doi.org/10.1016/S1470-2045(18)30010-X.CrossRefPubMed

74.

• DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Blood. 2018. https://doi.org/10.1182/blood-2018-08-868752. In this large phase Ib study in newly diagnosed elderly AML patients, venetoclax combined with hypomethylating agents led to a high remission rate and an overall survival higher than expected in this population.

75.

DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401–7. https://doi.org/10.1002/ajh.25000.CrossRefPubMed

76.

Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103:e404–7. https://doi.org/10.3324/haematol.2018.188094.

77.

Teh T-C, Nguyen N-Y, Moujalled DM, Segal D, Pomilio G, Rijal S, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia. 2018;32:303–12. https://doi.org/10.1038/leu.2017.243.CrossRefPubMed

78.

Glass J, Hassane DC, Wouters B, Kunimoto H, Avellino R, Garrett-Bakelman FE, et al. Epigenetic identity in AML depends on disruption of non-promoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers. Cancer Discov. 2017:CD-16-1032. https://doi.org/10.1158/2159-8290.CD-16-1032.

79.

Ritchie EK, Feldman EJ, Christos PJ, Rohan SD, Lagassa CB, Ippoliti C, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54:2003–7. https://doi.org/10.3109/10428194.2012.762093.CrossRefPubMed

80.

Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–36. https://doi.org/10.1056/NEJMoa1605949.CrossRefPubMedPubMedCentral

81.

Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia TM, Huang X, et al. Randomized phase II trial of two schedules of decitabine as frontline therapy in elderly patients with acute myeloid leukemia ineligible for standard cytotoxic induction regimens. Blood. 2016;128:1612.CrossRef

82.

Huls G, Chitu D, Havelange V, Jongen-Lavrencic M, Loosdrecht A van de, Biemond BJ, et al. Randomized maintenance therapy with azacitidine (vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). results of the HOVON97 phase III randomized multicentre study (EudraCT 2008-001290-15). ASH Meeting Abstracts 2017;130:463–463.

83.

Rashidi A, Walter RB, Tallman MS, Appelbaum FR, DiPersio JF. Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. Blood. 2016;128:763–73. https://doi.org/10.1182/blood-2016-03-674127.CrossRefPubMedPubMedCentral

84.

Cornelissen JJ, Norden Y van, Gelder M van, Breems DA, Maertens J, Jongen-Lavrencic M, et al. Early post-transplant epigenetic therapy by panobinostat and decitabine followed by donor lymphocyte infusion (DLI): interim results of the HOVON-116 phase I/II feasibility study in poor-risk AML recipients of allogeneic stem cell transplantation (alloHSCT). ASH Meeting Abstracts. 2016;128:832–832.

85.

Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29:2521–7. https://doi.org/10.1200/JCO.2010.34.4226.CrossRefPubMedPubMedCentral

86.

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O’Connell CL, Tibes R, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017;18:1317–26. https://doi.org/10.1016/S1470-2045(17)30576-4.CrossRefPubMedPubMedCentral

87.

Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O’Connell CL, Griffiths EA, et al. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia: activity and safety of Guadecitabine in AML. Cancer. 2018;124:325–34. https://doi.org/10.1002/cncr.31138.CrossRefPubMed

88.

Hansen R. Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy – Astex Available: https://astx.com/astex-pharmaceuticals-and-otsuka-announce-results-of-the-phase-3-astral-1-study-of-guadecitabine-sgi-110-in-treatment-naive-aml-patients-ineligible-to-receive-intense-induction-chemotherapy/

89.

Schuh AC, Döhner H, Pleyer L, Seymour JF, Fenaux P, Dombret H. Azacitidine in adult patients with acute myeloid leukemia. Crit Rev Oncol Hematol. 2017;116:159–77. https://doi.org/10.1016/j.critrevonc.2017.05.010.CrossRefPubMed

90.

Manero GG, Atallah E, Khaled SK, Arellano M, Patnaik MM, Odenike O, et al. A phase 2 study of pracinostat and azacitidine in elderly patients with acute myeloid leukemia (AML) not eligible for induction chemotherapy: response and long-term survival benefit. ASH Meeting Abstracts. 2016;128:100–100.

91.

Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018;131:1415–24. https://doi.org/10.1182/blood-2017-09-805895.CrossRefPubMedPubMedCentral

92.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016;3:e186–95. https://doi.org/10.1016/S2352-3026(15)00247-1.CrossRefPubMed

93.

Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018;131:2661–9. https://doi.org/10.1182/blood-2017-12-818948.CrossRefPubMedPubMedCentral

94.

Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, et al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia. 2018;32:1621–30. https://doi.org/10.1038/s41375-018-0129-6.CrossRefPubMed

95.

Hills RK, Burnett AK. Applicability of a “Pick a Winner” trial design to acute myeloid leukemia. Blood. 2011;118:2389–94. https://doi.org/10.1182/blood-2011-02-337261.CrossRefPubMed

96.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526–31. https://doi.org/10.1038/s41586-018-0623-z.CrossRefPubMedPubMedCentral

97.

Beyar-Katz O, Gill S. Novel approaches to acute myeloid leukemia immunotherapy. Clin Cancer Res. 2018;24:5502–15. https://doi.org/10.1158/1078-0432.CCR-17-3016.CrossRefPubMed

98.

Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49:332–40. https://doi.org/10.1038/ng.3756.CrossRefPubMedPubMedCentral

Titel: New Treatment Options for Acute Myeloid Leukemia in 2019
verfasst von: Marco Cerrano
Raphael Itzykson
Publikationsdatum: 01.02.2019
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 2/2019
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-019-0764-8

Novel Approaches for Treating Pain in Children

Palliative Medicine (A Jatoi, Section Editor)

BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer

Evolving Therapies (RM Bukowski, Section Editor)

Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?

Leukemia (A Aguayo, Section Editor)

Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid

Palliative Medicine (A Jatoi, Section Editor)

Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics

Evolving Therapies (RM Bukowski, Section Editor)

TRK Inhibitors: Clinical Development of Larotrectinib

Evolving Therapies (RM Bukowski, Section Editor)

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

20.04.2025
Melanom
Nachrichten

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

17.04.2025
AAN-Jahrestagung 2025
Kongressbericht

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

17.04.2025
DGP 2025
Kongressbericht

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

17.04.2025
Koloskopie
Nachrichten

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

New Treatment Options for Acute Myeloid Leukemia in 2019

Abstract

Purpose of Review

Recent Findings

Summary

Weitere Artikel der Ausgabe 2/2019

Novel Approaches for Treating Pain in Children

BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer

Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?

Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid

Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics

TRK Inhibitors: Clinical Development of Larotrectinib

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten